Business Context and Reporting Period
This Form 8-K Current Report from IDEAYA Biosciences, Inc. (IDYA) covers events occurring on January 12, 2024, and was filed on January 16, 2024. The report details the completion of a specific equity offering under an existing at-the-market (ATM) facility.
Key Financial Metrics
- Shares Sold: 1,561,735 shares of common stock.
- Net Proceeds: Approximately $57.0 million.
- Weighted Average Sales Price: Approximately $37.60 per share.
- Remaining ATM Capacity: $0 (The facility was fully utilized as of January 15, 2024).
Material Changes
The primary material change reported is the full exhaustion of the $250.0 million ATM facility established on June 26, 2023, with Jefferies LLC. The January 12, 2024 transaction represented the final tranche of shares sold under this specific agreement, leaving no remaining capacity for future sales under the June 2023 Sales Agreement.
Outlook and Management Commentary
The filing does not provide forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the standard disclosure of the completed transaction. The report confirms the Company's status as a "well-known seasoned issuer" utilizing its shelf registration (File No. 333-272936).
Investor Verification Checklist
- Verify the exact net proceeds received after deducting sales agent commissions and expenses.
- Confirm whether the Company has filed a new ATM agreement or shelf registration to replace the exhausted June 2023 facility.
- Review the Company's most recent 10-Q or 10-K to assess how these $57.0 million in proceeds impact overall liquidity and cash runway.
- Check for any subsequent filings regarding the use of proceeds or new capital raising activities.